Status:
RECRUITING
A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Extensive-Stage Small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The Purpose of the Study is to Compare the Efficacy and Safety of BMS-986489 (Anti-fucosyl-GM1+ Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide to that of Atezolizumab...
Eligibility Criteria
No eligibility criteria provided.
Key Trial Info
Start Date :
February 25 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 5 2031
Estimated Enrollment :
530 Patients enrolled
Trial Details
Trial ID
NCT06646276
Start Date
February 25 2025
End Date
September 5 2031
Last Update
March 4 2026
Active Locations (184)
Enter a location and click search to find clinical trials sorted by distance.
1
Southern Cancer Center, PC
Daphne, Alabama, United States, 36526
2
Local Institution - 0283
Hot Springs, Arkansas, United States, 71913
3
Florida Cancer Specialists - South
Fort Myers, Florida, United States, 33901
4
Mid Florida Hematology and Oncology Center
Orange City, Florida, United States, 32763